SeekingAlpha · Aug 25, 2026
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
Dianthus Therapeutics (DNTH) outlook: $1.2B cash funds neuromuscular pipeline through 2030 as claseprubart nears key 2026-27 readouts. See more here.
DN
NASDAQ · DNTH
Dianthus Therapeutics, Inc.
Healthcare · Biotechnology
$111.54
Up+$0.78 (+0.70%)
Updated Aug 28, 2026, 11:00 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.51B
- P/E ratio
- -12.45
- Dividend yield
- 0.00%
- 52-week range
- $68.85 – $117.88
- Volume
- 601.23K
- Avg. volume
- 657.86K
Price performance
DNTH price history
1M range · 21 trading sessions · Daily adjusted prices
DNTH closed at $111.54 after 21 trading sessions, down 0.98% for the selected period.
- Last close
- $111.54
- Period change
- -0.98%
- Period low
- $106.02
- Period high
- $115.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $111.28 | $112.13 | $109.6894 | $111.54 | 601.23K |
| Aug 26, 2026 | $111.44 | $111.56 | $109.54 | $110.76 | 335.36K |
| Aug 25, 2026 | $112.23 | $113.86 | $110.20 | $112.11 | 552.02K |
| Aug 24, 2026 | $110.08 | $111.805 | $105.05 | $110.07 | 531.93K |
| Aug 21, 2026 | $110.30 | $112.72 | $108.9521 | $111.10 | 730.87K |
| Aug 20, 2026 | $111.73 | $112.82 | $107.36 | $109.51 | 735.48K |
| Aug 19, 2026 | $117.66 | $117.875 | $112.79 | $113.70 | 793.27K |
| Aug 18, 2026 | $113.50 | $116.30 | $112.33 | $115.54 | 464.29K |
| Aug 17, 2026 | $115.32 | $116.89 | $113.2935 | $114.86 | 581.64K |
| Aug 14, 2026 | $108.96 | $116.47 | $108.765 | $115.96 | 903.47K |
| Aug 13, 2026 | $112.96 | $113.07 | $109.00 | $109.60 | 411.05K |
| Aug 12, 2026 | $109.37 | $113.645 | $108.36 | $112.41 | 654K |
| Aug 11, 2026 | $111.82 | $112.085 | $107.96 | $108.49 | 778.22K |
| Aug 10, 2026 | $107.69 | $111.83 | $106.24 | $111.80 | 861.27K |
| Aug 7, 2026 | $111.60 | $113.35 | $106.88 | $108.92 | 570.47K |
| Aug 6, 2026 | $111.93 | $114.14 | $106.86 | $109.92 | 708.37K |
| Aug 5, 2026 | $109.89 | $112.78 | $108.01 | $112.50 | 1.05M |
| Aug 4, 2026 | $106.95 | $111.17 | $106.79 | $110.40 | 636.62K |
| Aug 3, 2026 | $105.64 | $107.3799 | $103.06 | $106.02 | 841.86K |
| Jul 31, 2026 | $113.06 | $114.55 | $105.66 | $106.92 | 1.08M |
| Jul 30, 2026 | $104.16 | $112.96 | $104.10 | $112.64 | 929.63K |
Latest DNTH news
The latest Smart Investors Daily articles mentioning DNTH.
Stock researchCompany · Overview
DNTH research
Overview
Company profile and research snapshot.
Company profile
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $67.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 5, 2026 | Wedbush | Outperform | — |
| Aug 3, 2026 | Evercore ISI Group | Outperform | — |
| May 6, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 6, 2026
Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $110 to $128.
Benzinga · Aug 6, 2026
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $130 to $158.
Benzinga · Aug 5, 2026
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
